



## 2025 APPHON/ROHPPA Conference Program

**May 1 to 3**

***IWK – 5850/5980 University Ave, Halifax NS | Virtual via MS Teams***

---

### Agenda

---

#### **DAY ONE**

Thursday, May 1<sup>st</sup>

- 1200 Registration and light Lunch
- 1300 Welcome and Introductions
- 1305 Hem/Onc Case Review – Dr. Lisa Goodyear
- 1335 Discussion/Q&A
- 1345 Chronic Transfusion Therapy – Jill Mitchell & Chantale Deyoung
- 1420 Discussion/Q&A
- 1430 Break
- 1445 Iron in the community – Dr. Lisa Pinto
- 1520 Discussion/Q&A
- 1530 Adjourn

#### **DAY TWO**

Friday, May 2<sup>nd</sup>

- 0800 Registration and Coffee
- 0830 Welcome
- 0845 Cardio Oncology – Mary Stuart
- 0908 Discussion/Q&A
- 0915 When a child or parent says 'no' to treatment – Amanda Porter
- 0950 Discussion/Q&A
- 1000 Break
- 1015 SSPedi: Symptom Screening in Pediatrics Tool – Dr. Lillian Sung,  
Guest Speaker
- 1105 Discussion/Q&A
- 1115 Precision Medicine in Pediatric Oncology: Expanding the Playing  
Field, or a Whole New Game? – Dr. Chelsea Ash
- 1150 Discussion/Q&A
- 1200 AGM – Carol Digout
- 1215 Lunch



**DALHOUSIE  
UNIVERSITY**

CONTINUING PROFESSIONAL  
DEVELOPMENT &  
MEDICAL EDUCATION

1300 Hodgkin's Lymphoma Update – Dr. Ketan Kulkarni  
 1335 Discussion/Q&A  
 1345 Provincial Meetings (break served in rooms) – Interactive/Workshop Session  
 1515 COG updates: Spring 2025 – Dr. Craig Erker  
 1550 Discussion/Q&A  
 1600 Adjourn

### DAY THREE

Saturday, May 3<sup>rd</sup>  
 0830 Coffee  
 0900 Welcome  
 0915 Blinatumomab, part 1 – Christa Wheeler Thorne, Marjorie McGibbon, Misty Spencer and Tonette Despres  
 0938 Discussion/Q&A  
 0945 Blinatumomab, part 2 – Dr. Joanne Delaney  
 1008 Discussion/Q&A  
 1015 Discipline specific meetings (break served in rooms) – Interactive/Workshop Session  
 1130 Oncofertility – Sarah Keeping and Toni Leamon  
 1153 Discussion/Q&A  
 1200 Lunch  
 1245 Pediatric Oncology Palliative Care in Atlantic Canada: A Needs Assessment – Erin Thorne  
 1308 Discussion/Q&A  
 1315 The financial impact of pediatric cancer treatment to families treated at the IWK – Zara Forbrigger  
 1338 Discussion/Q&A  
 1345 Leukemia and Lymphoma Society of Canada – Brooke Dewhurst  
 1356 Discussion/Q&A  
 1400 Guidelines Update – Dr. Tamara MacDonald  
 1435 Discussion/Q&A  
 1445 Adjourn

## Speakers – Topics – Learning Objectives

### Thursday, May 1

**Dr. Lisa Goodyear**

#### ***Hem/Onc Case Review***

At the conclusion of this activity, participants will be able to:

1. Interpret common and uncommon pediatric hematology bloodwork findings by applying clinical reasoning to real-world case scenarios. (medical expert, scholar)
2. Develop a systematic approach to generating a differential diagnosis based on abnormal bloodwork results and identifying key next steps in the diagnostic work-up. (medical expert, scholar, communicator)
3. Formulate appropriate management plans for pediatric patients based on bloodwork findings, incorporating evidence-based decision-making and multidisciplinary collaboration. (medical expert, collaborator, leader)

**Jill Mitchell & Chantale Deyoung**

#### ***Chronic Transfusion Therapy***

At the conclusion of this activity, participants will be able to:

1. Recognize the purpose and benefits of chronic transfusion therapy.
2. Identify potential risks and complications.
3. Explain the process of chronic transfusion therapy.

**Dr. Lisa Pinto**

#### ***Iron in the community***

At the conclusion of this activity, participants will be able to:

1. Describe an approach to management of iron deficiency and iron deficiency anemia.
2. Identify indications for use of intravenous iron infusions.
3. Describe risks and benefits associated with intravenous iron infusions.
4. Describe an approach to management of iron deficiency anemia with intravenous iron when indicated.



## Friday, May 2

**Mary Stuart**

### ***Cardio Oncology***

At the conclusion of this activity, participants will be able to:

1. Discuss the development of Canadian and an international collaboration in cardiology and oncology, current nursing involvement, and current research ongoing.
2. Provide an overview of anthracyclines, targeted therapy and radiation and impact on pediatric cancer patients. Evaluate research on co-morbidities impacting pediatric patients pre and post treatment.
3. Identify what health care providers can do to change this trajectory. Assess recent research in nutrition and exercise as potential areas of focus as clinicians.
4. Define the current recommendations on cardiac surveillance and imaging from recent ASE 2024 guidelines.
5. Demonstrate a knowledge of resources.

**Amanda Porter**

### ***When a child or parent says 'no' to treatment***

At the conclusion of this activity, participants will be able to:

1. Identify some of the ethical challenges that surround a declining of treatment by a patient of their substitute decision maker.
2. Build capacity for engaging in informed discussion of these kinds of cases.

**Dr. Lillian Sung, Guest Speaker**

### ***SSPedi: Symptom Screening in Pediatrics Tool***

At the conclusion of this activity, participants will be able to:

1. Identify the importance of symptoms in pediatric patients with cancer.
2. Explain the results of recent trials evaluating routine symptom screening in pediatric patients with cancer.
3. Recognize approaches to manage symptoms identified through symptom screening.

**Dr. Chelsea Ash**

### ***Precision Medicine in Pediatric Oncology: Expanding the Playing Field, or a Whole New Game?***

At the conclusion of this activity, participants will be able to:

1. Recognize the historical evolution of precision cancer medicines including that of prominent precision therapies in pediatric oncology. (medical expert, scholar)
2. Identify how targeted agents might complement, and potentially replace, conventional treatment approaches. (medical expert, collaborator)
3. Identify barriers to the development and clinical use of precision therapies in the pediatric population. (health advocate)

**Dr. Ketan Kulkarni**

### ***Hodgkin's Lymphoma Update***

At the conclusion of this activity, participants will be able to:

1. Demonstrate the knowledge of new treatments for Hodgkin's Lymphoma.
2. Differentiate when the patient can be in the community versus IWK.
3. State the evidence for treatment of Hodgkin's Lymphoma.

### **Provincial Meetings – Interactive/Workshop Session**

- See insert for learning objectives

**Dr. Craig Erker**

### ***COG updates: Spring 2025***

At the conclusion of this activity, participants will be able to:

1. Discuss the Children's Oncology Group (COG).
2. Describe updates on clinical trial results.
3. Identify upcoming trials through COG.

## Saturday, May 3

**Marjorie McGibbon, Misty Spencer, and Tonette Despres**

### ***Blinatumomab, part 1***

At the conclusion of this activity, participants will be able to:

1. Identify care requirements for Blinatumomab therapy provision in advanced center community hospitals specifically in NB.
2. State the constraints that come with rehoming and providing this care in advanced center community hospitals.
3. Breakdown the successes demonstrated and what made this successful.
4. Summarize overall lessons learned from Moncton and how they can be applied to all advanced centre community hospitals.

**Dr. Joanne Delaney**

### ***Blinatumomab, part 2***

At the conclusion of this activity, participants will be able to:

1. Review the role of blinatumomab in upfront treatment of B-cell pediatric acute lymphoblastic leukemia.
2. Review common complications of blinatumomab and discuss management strategies.

### **Discipline-Specific Meetings – Interactive/Workshop Session**

- See insert for learning objectives



## **Sarah Keeping and Toni Leamon**

### ***Oncofertility***

At the conclusion of this activity, participants will be able to:

1. Identify the intended outcomes of the CPAC/APPHON oncofertility project for pediatric and young adult oncology patients and healthcare providers in Atlantic Canada.
2. Recognize the importance of timely fertility discussions and accurate documentation of these encounters.
3. State the role of provincial oncofertility guidelines and recommendations, including clinical care pathways, and how they can be utilized for evidence-based patient care.

## **Erin Thorne**

### ***Pediatric Oncology Palliative Care in Atlantic Canada: A Needs Assessment***

At the conclusion of this presentation, participants will be able to:

1. Identify the key needs and challenges in delivering pediatric oncology palliative care across healthcare facilities in Atlantic Canada, as reported by healthcare providers.
2. Describe healthcare providers' perceptions and experiences regarding the integration of palliative care into pediatric oncology.
3. Discuss the findings of the survey responses and the preliminary results of focus group discussions on recommendations for optimizing delivery of pediatric palliative care in Atlantic Canada.

## **Zara Forbrigger**

### ***The financial impact of pediatric cancer treatment to families treated at the IWK***

At the conclusion of this activity, participants will be able to:

1. Identify the out-of-pocket travel expenses families experienced travelling to the IWK for treatment.
2. Recognize the impact of these financial burdens on families.

## **Brooke Dewhurst**

### ***Leukemia and Lymphoma Society of Canada***

At the conclusion of this activity, participants will be able to:

1. Describe the range of pediatric programs and services offered by the Leukemia and Lymphoma Society of Canada.
2. Recognize the various ways they can partner with the LLSC through referrals, continuing education, and upcoming events.

## **Dr. Tamara MacDonald**

### ***Guidelines Update***

At the conclusion of this activity, participants will be able to:

- Review C. diff guidelines.
- Review immunization updates.

---

## Scientific Planning Committee

---

Dr. Bruce Crooks  
Carol Digout  
Céline Richard  
Stephanie Eason  
Dr. Natacha Hébert  
Dr. Tamara MacDonald  
Marjorie McGibbon  
Christa McGuirk  
Jill Mitchell  
Holly Paynter

---

## Learning Objectives for the Conference

---

After attending this conference, participants will discover new guidelines, practices, literature, and treatment of patients with hematologic/oncologic diseases.



Educationally approved by Dalhousie University Continuing Professional Development and Medical Education.

This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by Dalhousie University Continuing Professional Development and Medical Education. You may claim a maximum of 13.0 hours (credits are automatically calculated).

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at: [edhub.ama-assn.org/pages/applications](https://edhub.ama-assn.org/pages/applications).

In keeping with CMA Guidelines, program content and selection of speakers are the responsibility of the planning committee. Support is directed toward the costs of the course and not to individual speakers through an unrestricted educational grant.

---

## Funding Sponsors

---

This program has received an educational grant / sponsorship or in-kind support from:

